Randomized trials to optimize treatment of multidrug-resistant tuberculosis
2007
Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis
publication
Evidence: high
Author Information
Author(s): Carole D. Mitnick, Kenneth G. Castro, Mark Harrington, Leonard V. Sacks, William Burman
Primary Institution: Harvard Medical School
Hypothesis
The time is now right for randomized trials of MDR-TB.
Conclusion
Randomized trials are essential to identify safe and effective regimens for treating multidrug-resistant tuberculosis.
Supporting Evidence
- Drug-resistant tuberculosis accounts for 10% of new TB cases annually.
- Current MDR-TB treatment outcomes are suboptimal, with many patients dying during treatment.
- New drug classes for MDR-TB are under development and need evaluation.
Takeaway
We need to test new treatments for a serious type of tuberculosis that is hard to cure, so we can help more people get better.
Methodology
The article discusses the need for randomized clinical trials to evaluate new drug regimens for MDR-TB.
Limitations
Current treatment regimens for MDR-TB are long, toxic, and often unsuccessful.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website